Simulations Plus has announced strategic collaboration programs with three large pharmaceutical companies, aimed at advancing AI-enabled workflows across the drug development lifecycle. The programs aim to integrate internally developed AI agents into model-informed drug development (MIDD) workflows, enabling natural language interaction, data processing automation, multi-engine simulation coordination, and interpretable outputs from complex pipelines.
Key platforms involved include GastroPlus®, MonolixSuite™, ADMET Predictor®, and Thales™. The collaborations also aim to establish governance standards around transparency and reproducibility, while aligning with IT teams to define how AI capabilities are deployed and integrated within existing enterprise systems.
Click to read more..
Image generated by: Gemini